Details

Autor(en) / Beteiligte

• Bhatt, Deepak L
• Cryer, Byron L
• Contant, Charles F
• Cohen, Marc
• Lanas, Angel
• Schnitzer, Thomas J
• Shook, Thomas L
• Lapuerta, Pablo
• Goldsmith, Mark A
• Laine, Loren
• Scirica, Benjamin M
• Murphy, Sabina A
• Cannon, Christopher P

Titel

Clopidogrel with or without Omeprazole in Coronary Artery Disease

Ist Teil von

• The New England journal of medicine, 2010-11, Vol.363 (20), p.1909-1917

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• In patients receiving dual antiplatelet therapy, omeprazole reduced the risk of upper-GI toxic effects but did not increase the risk of cardiovascular events; statistical power to assess cardiovascular events was low, however, so the findings are not definitive. On the basis of data from several studies, clopidogrel has become the second most commonly used prescription drug worldwide. 1 – 9 Gastrointestinal hemorrhage is the most common serious bleeding complication from the use of long-term antiplatelet therapy. 10 , 11 Data from randomized studies support the concept that therapies reducing acidity decrease gastrointestinal complications of antiplatelet therapy involving aspirin, though the data are largely based on endoscopic end points; observational data also support this effect. 12 – 16 Randomized, controlled trials have shown that proton-pump inhibitors (PPIs) reduce the rate of recurrent gastrointestinal bleeding in high-risk patients receiving aspirin. 17 Observational studies, however, have suggested that . . .